| 朱艳华,曾凡业,张洪亮,樊玉详,张立平,节阳华,李学云.益气健脾汤联合腹腔热灌注化疗用于结直肠癌术后的临床疗效及对患者血清TK1、COX-2、sICAM-1水平的影响[J].,2019,19(10):1907-1911 |
| 益气健脾汤联合腹腔热灌注化疗用于结直肠癌术后的临床疗效及对患者血清TK1、COX-2、sICAM-1水平的影响 |
| Clinical Efficacy of Yiqi Jianpi Decoction Combined with Intraperitoneal Hyperthermic Chemotherapy in the Treatment of Colorectal Cancer after Operation and Its Effect on the Serum TK1, COX-2 and sICAM-1 Levels |
| 投稿时间：2018-09-26 修订日期：2018-10-21 |
| DOI：10.13241/j.cnki.pmb.2019.10.021 |
| 中文关键词: 益气健脾汤 结直肠癌 腹腔热灌注化疗 生活质量 |
| 英文关键词: Yiqi Jianpi Decoction Colorectal cancer Intraperitoneal hyperthermic perfusion chemotherapy Quality of life |
| 基金项目:新疆维吾尔自治区自然科学基金项目(2014D01C178) |
|
| 摘要点击次数: 876 |
| 全文下载次数: 726 |
| 中文摘要: |
| 摘要 目的：探讨益气健脾汤联合腹腔热灌注化疗用于结直肠癌术后的临床疗效及对患者血清胸苷激酶1(TK1)、环氧化酶-2(COX-2)与可溶性细胞间黏附分子-1(sICAM-1)水平的影响。方法：选择本院2014年2月到2016年2月收治的结直肠癌患者62例进行回顾性分析，采用系统随机的方法降所有患者分为对照组和治疗组，每组各31例。对照组采用腹腔热灌注化疗进行治疗，治疗组采用益气健脾汤联合腹腔热灌注化疗进行治疗。观察和比较两组患者治疗后的临床疗效、生活质量改善情况、24个月内生存率、治疗前后的血清TK1、COX-2、sICAM-1水平的变化及不良反应的发生情况。结果：治疗后，观察组患者总有效率为93.55%，明显高于对照组(77.42%，P<0.05)；两组患者的血清TK1、COX-2、sICAM-1水平较治疗前显著降低(P<0.05)；且观察组血清TK1、COX-2、sICAM-1水平明显低于对照组(P<0.05)；观察组患者生活质量改善总有效率为95.55%，明显高于对照组(77.78%，P<0.05)；治疗组患者24个月内生存率为67.74%，明显高于对照组患者(32.26%，P<0.05)。两组不良反应的发生情况比较差异无明显统计学意义(P>0.05)。结论：益气健脾汤联合腹腔热灌注化疗用于结直肠癌术后的临床疗效显著，可以有效改善患者的生存质量和预后，且安全性高，可能与其显著降低血清TK1、COX-2、sICAM-1水平有关。 |
| 英文摘要: |
| ABSTRACT Objective: To explore the clinical efficacy of Yiqi Jianpi Decoction combined with intraperitoneal hyperthermic perfusion chemotherapy in the treatment of postoperative colorectal cancer and its effect on the serum thymidine kinase 1 (TK1), cyclooxygenase-2 (COX-2) and soluble intercellular adhesion molecule. The effect of -1 (sICAM-1) levels. Methods: A retrospective analysis of 62 patients with colorectal cancer admitted to our hospital from February 2014 to February 2016 was performed. All patients were divided into the control group and the treatment group according to the systematic randomization method, with 31 cases in each group. The control group was treated with intraperitoneal hyperthermic perfusion chemotherapy. The treatment group was treated with Yiqi Jianpi Decoction combined with intraperitoneal hyperthermic perfusion chemotherapy. The clinical efficacy, improvement of quality of life, survival rate within 24 months, serum TK1, COX-2, sICAM-1 levels and incidence of adverse reactions before and after treatment were observed and compared between the two groups. Results: After treatment, the total effective rate of observation group was 93.55%, which was significantly higher than that of the control group (77.42%, P<0.05). The serum levels of TK1, COX-2 and sICAM-1 in both groups were significantly lower than those before treatment (P<0.05). The levels of serum TK1, COX-2 and sICAM-1 in the observation group were significantly lower than those in the control group (P<0.05). The total effective rate of improvement in quality of life in the observation group was 95.55%, which was significantly higher than that of the control group (77.78%, P < 0.05). The survival rate in the treatment group was 67.74% within 24 months, which was significantly higher than that in the control group (32.26%, P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P>0.05). Conclusion: Yiqi Jianpi Decoction combined with intraperitoneal hyperthermic perfusion chemotherapy has significant clinical efficacy in the treatment of colorectal cancer with high safety, which can effectively improve the quality of life and prognosis of patients. It may be related to the decrease of serum TK1, COX-2, sICAM- 1 levels. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
